Details for New Drug Application (NDA): 217628
✉ Email this page to a colleague
NDA 217628 describes CLOTIC, which is a drug marketed by Carwin Pharm Assoc and is included in one NDA. There is one patent protecting this drug. Additional details are available on the CLOTIC profile page.
The generic ingredient in CLOTIC is clotrimazole. There are eleven drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the clotrimazole profile page.
The generic ingredient in CLOTIC is clotrimazole. There are eleven drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the clotrimazole profile page.
Summary for 217628
| Tradename: | CLOTIC |
| Applicant: | Carwin Pharm Assoc |
| Ingredient: | clotrimazole |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 217628
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OTIC | Strength | 1% | ||||
| Approval Date: | Sep 26, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 26, 2033 | ||||||||
| Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
| Regulatory Exclusivity Expiration: | Sep 26, 2028 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | 12,246,006 | Patent Expiration: | May 26, 2042 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF FUNGAL OTIC INFECTION (FUNGAL OTITIS EXTERNA, OTOMYCOSIS) DUE TO ASPERGILLUS SPECIES AND CANDIDA SPECIES | ||||||||
Complete Access Available with Subscription
